Home › Funds › TCG Crossover Management, LLC › GLUE
TCG Crossover Management, LLC position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
TCG Crossover Management, LLC reported holding 3,781,532 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$45.1M, representing 1.27% of its reported portfolio and ranking #25 among its reported holdings. TCG Crossover Management, LLC has disclosed GLUE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's GLUE position evolved
TCG Crossover Management, LLC first disclosed a stake in GLUE in Q4 2025 at 4,622,151 shares (US$72.5M). The position peaked in Q2 2026 at 4,622,151 shares, worth US$111.9M. Across 4 filings, TCG Crossover Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 3,781,532 shares valued at US$45.1M — a reduction of -840,619 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 4.62M | $72.48M | New |
| Q1 2026 | 4.62M | $76.03M | Hold |
| Q2 2026 | 4.62M | $111.86M | Hold |
| Q3 2026 | 3.78M | $45.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 59 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), Vestal Point Capital, LP (US$111.3M), BVF INC/IL (US$108.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $37.95M · Q3 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $18.56M · Q3 2026
- Nextech Invest Ltd. 761.15K sh · $18.42M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held GLUE?
TCG Crossover Management, LLC has disclosed GLUE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is TCG Crossover Management, LLC's current position in GLUE?
As of Q3 2026, TCG Crossover Management, LLC holds 3.78M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $45.11M, representing 1.27% of its reported portfolio and ranking #25.
Has TCG Crossover Management, LLC been buying or selling GLUE?
In the latest 13F filing (Q3 2026), TCG Crossover Management, LLC reduced its position in GLUE. The position peaked in Q2 2026 at 4.62M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, Vestal Point Capital, LP, BVF INC/IL, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.